1. Home
  2. STLD vs BIIB Comparison

STLD vs BIIB Comparison

Compare STLD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Steel Dynamics Inc.

STLD

Steel Dynamics Inc.

HOLD

Current Price

$239.62

Market Cap

33.6B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$218.12

Market Cap

29.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STLD
BIIB
Founded
1993
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6B
29.9B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
STLD
BIIB
Price
$239.62
$218.12
Analyst Decision
Buy
Buy
Analyst Count
9
25
Target Price
$210.00
$206.83
AVG Volume (30 Days)
1.1M
630.6K
Earning Date
04-20-2026
04-29-2026
Dividend Yield
0.94%
N/A
EPS Growth
N/A
N/A
EPS
6.47
2.15
Revenue
$22,260,774,000.00
$9,890,600,000.00
Revenue This Year
$17.86
N/A
Revenue Next Year
$2.86
N/A
P/E Ratio
$37.20
$98.01
Revenue Growth
20.92
2.22
52 Week Low
$129.45
$135.39
52 Week High
$288.74
$225.80

Technical Indicators

Market Signals
Indicator
STLD
BIIB
Relative Strength Index (RSI) 44.95 51.39
Support Level $217.80 $184.50
Resistance Level $243.73 $219.24
Average True Range (ATR) 7.32 5.27
MACD 0.43 -1.05
Stochastic Oscillator 45.68 38.77

Price Performance

Historical Comparison
STLD
BIIB

About STLD Steel Dynamics Inc.

Steel Dynamics Inc operates as a domestic steel producer and metal recycler in the United States. The company's product portfolio comprises hot rolled sheet, hot rolled plate, painted sheet products, cold rolled sheet, and others. Its reportable segments are steel operations, metals recycling operations, steel fabrication operations, and aluminum operations. Maximum revenue is generated from its steel operations segment, which consists of manufacturing various steel products and numerous coating operations. Its primary sources of revenue are currently from the manufacture and sale of steel products, the processing and sale of recycled ferrous and nonferrous metals, and the fabrication and sale of steel joists and deck products.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: